HAEM5:In situ mantle cell neoplasm: Difference between revisions
| [checked revision] | [checked revision] |
Bailey.Glen (talk | contribs) |
No edit summary |
||
| Line 1: | Line 1: | ||
{{DISPLAYTITLE:In situ mantle cell neoplasm}} | {{DISPLAYTITLE:In situ mantle cell neoplasm}} | ||
[[HAEM5:Table_of_Contents|Haematolymphoid Tumours (WHO Classification, 5th ed.)]] | [[HAEM5:Table_of_Contents|Haematolymphoid Tumours (WHO Classification, 5th ed.)]] | ||
{{Under Construction}} | {{Under Construction}} | ||
<blockquote class= | <blockquote class="blockedit">{{Box-round|title=Content Update To WHO 5th Edition Classification Is In Process; Content Below is Based on WHO 4th Edition Classification|This page was converted to the new template on 2023-12-07. The original page can be found at [[HAEM4:In Situ Mantle Cell Neoplasia]]. | ||
}}</blockquote> | }}</blockquote> | ||
| Line 753: | Line 754: | ||
==Additional Information== | ==Additional Information== | ||
This disease is <u>defined/characterized</u> as detailed below: | |||
* The Latin phrase “in situ” means “in the natural or original position or place”, as per the Merriam-Webster dictionary. In normal benign lymphoid tissues, the mantle zones of lymphoid follicles are formed by naïve mature B-cells after maturation from precursor B-cells in the bone marrow. In situ mantle cell neoplasm is a pre-malignant neoplasm composed of mantle cells “in their natural position” that harbor, in addition, the t(11;14) balanced translocation characteristic of mantle cell lymphoma with the overexpression of cyclin D1 protein. | |||
* An in situ mantle cell neoplasm may precede, co-exist with, or may occur after the development of an overt mantle cell lymphoma. This pre-malignant neoplasm is more often identified in patients newly diagnosed with an overt mantle cell lymphoma in whom a retrospective examination of a prior reactive-appearing lymph node or lymphoid tissue biopsy shows the presence of in situ mantle cell neoplasm. In situ mantle cell neoplasm is only rarely diagnosed in lymph nodes diagnosed as benign or reactive lymphoid hyperplasia after biopsy for enlargement or other symptomatic causes. The diagnostic criteria for in situ mantle cell neoplasm are currently based primarily on histopathologic examination (description in the morphologic features section). The pathologic diagnosis of in situ mantle cell neoplasm requires distinguishing from two major disease entities: (1) reactive lymphoid hyperplasia, and (2) mantle cell lymphoma with a mantle zone pattern. Of note, in situ mantle cell neoplasm may co-exist with any overt mature B-cell lymphoma, including as a component of a composite lymphoma. | |||
The <u>epidemiology/prevalence</u> of this disease is detailed below: | |||
The <u>clinical features</u> of this disease are detailed below: | |||
Signs and symptoms - | |||
Laboratory findings - | |||
The <u>sites of involvement</u> of this disease are detailed below: | |||
The <u>morphologic features</u> of this disease are detailed below: | |||
The <u>immunophenotype</u> of this disease is detailed below: | |||
Positive (universal) - | |||
Positive (majority) - | |||
Positive (subset) - | |||
Negative (universal) - | |||
Negative (subset) - | |||
==Links== | ==Links== | ||
| Line 774: | Line 805: | ||
<nowiki>*</nowiki>''Citation of this Page'': “In situ mantle cell neoplasm”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/HAEM5:In_situ_mantle_cell_neoplasm</nowiki>. | <nowiki>*</nowiki>''Citation of this Page'': “In situ mantle cell neoplasm”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/HAEM5:In_situ_mantle_cell_neoplasm</nowiki>. | ||
[[Category:HAEM5]][[Category:DISEASE]][[Category:Diseases I]] | [[Category:HAEM5]] | ||
[[Category:DISEASE]] | |||
[[Category:Diseases I]] | |||